• Latest Posts

A Year to Remember: The Biggest European Biotech News in 2020

Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon

Genfit’s NASH Drug to Be Developed in China in Deal Worth up to €200M

Genfit Gets Ready to Launch Drug for Untreated Liver Disease Raising €120M

NASH Leader goes Pediatric with Clinical Trial Launch in US


Genfit Gets €180M Cash Injection to Bring its Pipeline to Market

These Three Fields Are Proving Biotech is The Innovation Powerhouse in Healthcare

Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy

Two Big Pharma Players Team up to Take Over the NASH Space